Just caught that Oppenheimer upgraded Vertex Pharmaceuticals to Outperform back in February, moving it from Perform. The price target sits around $532.50 per share, which implies about 8.35% upside from where it was trading at the time. Pretty interesting timing given what's been happening with the stock.

Looking at the fund positioning, there are roughly 2,469 institutions holding VRTX, though that's actually down about 208 holders from the previous quarter. The average fund allocation is 0.36% of portfolios, up 6.83% quarter-over-quarter. What caught my eye is that total institutional shares decreased by 5.88% to around 283 million shares, so there's some mixed signals there even with the Oppenheimer upgrade.

Capital World Investors remains the biggest player with about 25.5 million shares (10% ownership), though they trimmed their position slightly by 1.57%. Meanwhile, Capital Research Global Investors increased their stake by 4.41% to 17.3 million shares. The put/call ratio is sitting at 0.86, which leans bullish. Revenue projections show a 10.67% decline year-over-year to about 10.7 billion, so the Oppenheimer upgrade seems to be betting on something beyond just top-line growth. The non-GAAP EPS forecast is 19.52.

Not sure if this is a contrarian call or if Oppenheimer sees something the market's still pricing in. Worth keeping on the radar though, especially with these institutional moves.